PackageSizes:10x1g,25g,100g
ProductNumbers(withoutTMCS):12102-10x1,12102-25,and12102-100
ProductNumbers(with1%TMCS):12102T-10x1,12102T-25,and12102T-100
ProductName:BSTFA
AlternativeNames:N,O-Bis(trimethylsilyl)trifluoroacetamide;BSTFAderivitizationreagent;C9H18F3NOSi
SpecificationsAppearance:Clearandcolorlessliquid
Purity:is≥99%
Storage:20°C,protectedfrommoisture
Properties
PropertiesPhysicalState:Clearliquid
CAS#:25561-30-2
ChemicalFormula:C9H18F3NOSi
MolecularWeight:257.4
Density:0.969at25°C(Lit)
BoilingPoint:45-50°C(Lit)
RefractiveIndex:n20/D1.384(Lit)
TariffCode:3822.00.0000
AdditionalProductInformation:
BSTFAProductInformationBulletin
BSTFAMSDS
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
磷脂C、H、O、N、P固醇C、H、ODNA 和RNA一样 CHONP
http://care.diabetesjournals.org/cgi/content/abstract/31/8/1479
OBJECTIVE—Hyperglycemiaisariskfactorformicrovascularcomplicationsandmayincreasetheriskofcardiovasculardiseaseinpatientswithtype2diabetes.ThisstudytestedtheLDLcholesterol–loweringagentcolesevelamHCl(colesevelam)asapotentialnoveltreatmentforimprovingglycemiccontrolinpatientswithtype2diabetesonsulfonylurea-basedtherapy.
RESEARCHDESIGNANDMETHODS—A26-week,randomized,double-blind,placebo-controlled,parallel-group,multicenterstudywascarriedoutbetweenAugust2004andAugust2006toevaluatetheefficacyandsafetyofcolesevelamforreducingA1Cinadultswithtype2diabeteswhoseglycemiccontrolwasinadequate(A1C7.5–9.5%)withexistingsulfonylureamonotherapyorsulfonylureaincombinationwithadditionaloralanti-diabetesagents.Intotal,461patientswererandomized(230givencolesevelam3.75g/dayand231givenplacebo).Theprimaryefficacymeasurementwasmeanplacebo-correctedchangeinA1Cfrombaselinetoweek26intheintent-to-treatpopulation(lastobservationcarriedforward).
RESULTS—Theleastsquares(LS)meanchangeinA1Cfrombaselinetoweek26was–0.32%inthecolesevelamgroupand+0.23%intheplacebogroup,resultinginatreatmentdifferenceof–0.54%(P<0.001).TheLSmeanpercentchangeinLDLcholesterolfrombaselinetoweek26was–16.1%inthecolesevelamgroupand+0.6%intheplacebogroup,resultinginatreatmentdifferenceof–16.7%(P<0.001).FurThermore,significantreductionsinfastingplasmaglucose,fructosamine,totalcholesterol,non–HDLcholesterol,andapolipoproteinBweredemonstratedinthecolesevelamrelativetoplacebogroupatweek26.
CONCLUSIONS—ColesevelamimprovedglycemiccontrolandreducedLDLcholesterollevelsinpatientswithtype2diabetesreceivingsulfonylurea-basedtherapy.